611 results on '"Xu, Jian-Ming"'
Search Results
52. Ablation of steroid receptor coactivator-3 in mice impairs adipogenesis and enhances energy expenditure
53. The interaction between interferon-induced protein with tetratricopeptide repeats-1 and eukaryotic elongation factor-1A
54. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences
55. Adsorption of bensulfuron-methyl on kaolinite as influenced by Pb contamination
56. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
57. Correlation of MR perfusion-weighted imaging of prostatic cancer with tumor angiogenesis
58. [Untitled]Fiber optical sensor effectiveness in the human body
59. [Untitled]Fiber optical sensor effectiveness in the human body
60. Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours
61. Hydrolase-catalyzed Michael addition of 1,3-dicarbonyl compounds to α,β-unsaturated compounds in organic solvent
62. Synthesis and characterization of drug–saccharide conjugates by enzymatic strategy in organic media
63. A fast and highly efficient protocol for Michael addition of N-heterocycles to α,β-unsaturated compound using basic ionic liquid [bmIm]OH as catalyst and green solvent
64. Post‑radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma
65. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines
66. Document-Specific Statistical Machine Translation for Improving Human Translation Productivity
67. Derivation and Validation of a Prediction Rule for Estimating Advanced Colorectal Neoplasm Risk in Average-Risk Chinese
68. Hepatic veno-occlusive disease after taking Gynura Rhizome: The value of multidetector computed tomography in diagnosing the disease and evaluating the clinical therapeutic effect
69. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro
70. Traumatic abdominal wall hernia secondary to handlebar injury: a case report
71. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice
72. Fault-tolerant Control for Linear System Under Sensor Saturation Constraint
73. Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
74. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial
75. Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancer
76. Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice
77. Two-step sequential synthesis of pyrimidine derivatives containing a sugar branch via combining of enzymatic Michael addition/acylation
78. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people
79. Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats
80. Refined Estimate of the Incubation Period of Severe Acute Respiratory Syndrome and Related Influencing Factors
81. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects
82. Non-Fragile PID Stabilizing Controller on Second-Order Systems with Time Delay
83. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa™, ZD1839)
84. Characterization of sequence-dependent synergy between ZD1839 (‘Iressa’) and oxaliplatin
85. Combination of 5-Fluorouracil and Irinotecan on Modulation of Thymidylate Synthase and Topoisomerase I Expression and Cell Cycle Regulation in Human Colon Cancer LoVo Cells: Clinical Relevance
86. Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
87. Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
88. S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.
89. A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
90. Association of co-occuring mutations in exosomal DNA and clinical outcomes of patients with metastatic colorectal cancer.
91. Preparation of carbon nanotube/epoxy composite films with high tensile strength and electrical conductivity by impregnation under pressure
92. Computer-assisted diagnosis of early esophageal squamous cell carcinoma using narrow-band imaging magnifying endoscopy
93. PIK3CA mutations contribute to acquired cetuximab resistance in metastatic colorectal cancer patients
94. A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.
95. Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
96. Development of NKG2D chimeric antigen receptor-T cells as targeted therapy of liver cancer.
97. Circulating tumor DNA clone analysis to predict disease progression/indicates trastuzumab-resistant mechanism in advanced gastric cancer.
98. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
99. Postradiation ctDNA status as a prognostic factor in locally advanced esophageal squamous cell carcinoma.
100. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.